Proyecto de mejora de la “Biblioteca para todos” ubicada en el AA. HH. Torres de San Borja - Moche - Trujillo - La Libertad

RESUMEN En este proyecto de responsabilidad social, se propone la mejora de la biblioteca en el AA. HH. LasTorres de San Borja, Distrito de Moche, con la finalidad de jugar un papel importante en la educación de los niños, concientizando a la comunidad que la lectura es muy importante para su desarrollo mental y educativo. El reto que se afronta es inmenso, pues se busca promover e incentivar el hábito de la lectura. Fomentando el cuidado de los libros y mejorando la comprensión lectora de los niños. Haciendo uso de actividades recreativas relacionadas a los libros de la biblioteca. Es por eso que gracias al proyecto UNIONES “BIBLIOTECA PARA TODOS”, el trabajo en conjunto de estudiantes de UPN y en coordinación con la docente Marlies Cueva Urra, así como la participación de la comunidad, se logró desarrollar el proyecto: “Mejora de la Biblioteca para todos del AA.HH. Las Torres de San Borja en el Distrito de Moche”ABSTRACT In this project of social responsibility, is proposed the improvement of the library in the AA. HH. Torres de San Borja, District of Moche, with the purpose of playing an important role in the education of children, making the community aware that reading is very important for their mental and educational development. The challenge that faces is immense, because it seeks to promote and encourage the habit of reading. Promoting the care of books and improving reading comprehension of children. Making use of recreational activities related to library books. That is why thanks to the project UNIONS "BIBLIOTECA PARA TODOS", the joint work of UPN students and in coordination with the teacher Marlies Cueva Urra, as well as the participation of the community, the project was developed: "Improvement of the Library for all of AA.HH. Torres de San Borja in the District of Moche

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years